US PATENT SUBCLASS 424 / 133.1
.~ Structurally-modified antibody, immunoglobulin, or fragment thereof (e.g., chimeric, humanized, CDR-grafted, mutated, etc.)

Current as of: June, 1999
Click HD for Main Headings
Click for All Classes

Internet Version by PATENTEC © 1999      Terms of Use


424 /   HD   DRUG, BIO-AFFECTING AND BODY TREATING COMPOSITIONS

130.1  DF  IMMUNOGLOBULIN, ANTISERUM, ANTIBODY, OR ANTIBODY FRAGMENT, EXCEPT CONJUGATE OR COMPLEX OF THE SAME WITH NONIMMUNOGLOBULIN MATERIAL {18}
133.1.~ Structurally-modified antibody, immunoglobulin, or fragment thereof (e.g., chimeric, humanized, CDR-grafted, mutated, etc.) {3}
134.1  DF  .~.~> Antibody, immunoglobulin, or fragment thereof fused via peptide linkage to nonimmunoglobulin protein, polypeptide, or fragment thereof (i.e., antibody or immunoglobulin fusion protein or polypeptide)
135.1  DF  .~.~> Single chain antibody
136.1  DF  .~.~> Bispecific or bifunctional, or multispecific or multifunctional, antibody or fragment thereof

DEFINITION

Classification: 424/133.1

Structurally-modified antibody, immunoglobulin, or fragment thereof (e.g., chimeric, humanized, CDR-grafted, mutated, etc.):

(under subclass 130.1) Subject matter involving an antibody, immunoglobulin, or fragment thereof that is purposely altered with respect to its amino acid sequence or glycosylation, or with respect to its composition of heavy and light chains or immunoglobulin regions or domains, as compared with that found in nature; or wherein the antibody, immunoglobulin, or fragment thereof is part of a larger, synthetic protein.

(1) Note. Structurally-modified antibodies may be made by

chemical alteration or recombination of existing antibodies, or by various cloning techniques involving recombinant DNA or hybridoma technology.

(2) Note. Structurally-modified antibodies may be chimeric (i.e., comprising amino acid sequences derived from two or more nonidentical immunoglobulin molecules, such as interspecies combinations, etc.).

(3) Note. Structurally-modified antibodies may have domain deletions or substitutions (e.g., deletions of particular constant-region domains or substitutions of constant-region domains from other classes of immunoglobulins).

(4) Note. Structurally-modified antibodies may have deletions of particular glycosylated amino acids, or may have their glycosylation otherwise altered, which may alter their function.

(5) Note. While expression of cloned antibody genes in cells of species other than from which they originated may result in altered glycosylation of the product, compared with that found in nature, this subclass and indented subclasses are not meant to encompass such antibodies or fragments thereof unless such cloning is a deliberate attempt to alter their glycosylation. However, such antibodies or fragments thereof may still be classified here or in indented subclasses if they are structurally-modified in other ways (e.g., if they are single chain, etc.).

(6) Note. It is suggested that the patents of this subclass and indented subclasses be cross-referenced to the appropriate subclass(es) that provide for the binding specificities of these antibodies, if disclosed.